Charles Schwab Investment Management Inc. Buys 28,130 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Charles Schwab Investment Management Inc. increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 10.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 290,009 shares of the company's stock after acquiring an additional 28,130 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.76% of Tarsus Pharmaceuticals worth $9,538,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its position in Tarsus Pharmaceuticals by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company's stock worth $6,924,000 after purchasing an additional 29,465 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at $28,904,000. Creative Planning purchased a new stake in Tarsus Pharmaceuticals in the 3rd quarter worth about $362,000. Essex Investment Management Co. LLC acquired a new stake in Tarsus Pharmaceuticals during the 3rd quarter worth about $3,590,000. Finally, Lisanti Capital Growth LLC acquired a new stake in Tarsus Pharmaceuticals during the 3rd quarter worth about $1,311,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ:TARS traded up $0.16 on Tuesday, reaching $50.82. The company had a trading volume of 247,211 shares, compared to its average volume of 713,316. The stock has a market capitalization of $1.94 billion, a P/E ratio of -13.30 and a beta of 1.04. The stock has a 50-day moving average price of $43.22 and a 200 day moving average price of $33.90. Tarsus Pharmaceuticals, Inc. has a twelve month low of $16.75 and a twelve month high of $52.99. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TARS shares. The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research report on Friday, November 15th. William Blair upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $54.20.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.